Spring Bank Pharmaceuticals to Present Results from Preclinical Studies of SB 9200 in HBV and HCV at EASL 2016

MILFORD, Mass., March 31, 2016 -- Spring Bank Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing novel therapeutics using its proprietary chemistry platform, today announced that two posters on SB 9200, its most advanced product candidate, for the treatment of viral infections, including Hepatitis B virus (HBV) and respiratory syncytial virus (RSV), have been accepted for presentation at The International Liver Congress™ 2016, 51^st annual meeting of the European Association for the Study of the Liver (EASL), taking place April 13-17 at the Fira Barcelona Gran Via Conference Centre in Barcelona, Spain.

Details of Spring Bank’s poster presentations are as follows:

Poster Title: SB 9200, A Novel Agonist of Innate Immunity, Shows Potent Antiviral Activity Against Resistant HCV Variants
Date &Time: Thursday, April 14, 2016, 8:00 a.m. to 6:00 p.m. Central European Time
Abstract Number: 233
Session Title: Viral Hepatitis: Hepatitis C – clinical (new compounds, resistance)
Location: Hall 8.1, Poster Area 2

Poster Title: Antiviral Efficacy and Host Immune Response Induction with SB 9200, an Oral Prodrug of the Dinucleotide SB 9200, in Combination with Entecavir in the Woodchuck Model of Chronic Hepatitis B
Date & Time: Friday, April 15, 2016, 8:00 a.m. to 6:00 p.m. Central European Time
Abstract Number: 143
Session Title: Viral Hepatitis: Hepatitis B & D – clinical (therapy, new compounds, resistance)
Location: Hall 8.1, Poster Area 2

The full abstracts can be viewed here.

About European Association for the Study of the Liver (EASL)

Since 1966, when the association was founded, EASL has continued to grow from a small organization that played host to 70 participants at its first meeting, to becoming the leading liver association in Europe. EASL attracts the foremost hepatology experts as members and has an impressive track record in promoting research in liver disease, supporting wider education, and promoting changes in European liver policies. For more information about EASL, please visit https://ilc-congress.eu/. 

About Spring Bank Pharmaceuticals

Spring Bank Pharmaceuticals is a clinical-stage biopharmaceutical company engaged in the discovery and development of a novel class of therapeutics using its proprietary small molecule nucleic acid hybrid, or SMNH, chemistry platform. SMNH compounds are small segments of nucleic acids that the company designs to selectively target and modulate the activity of specific proteins implicated in various disease states. The company is developing its most advanced SMNH product candidate, SB 9200, for the treatment of viral diseases. SB 9200 has been designed to selectively activate within infected cells the cellular proteins, retinoic acid-inducible gene 1, or RIG-I, and nucleotide-binding oligomerization domain-containing protein 2, or NOD2, which have been implicated in the body’s immune response to viral infections. Spring Bank believes that SB 9200 may play an important role in antiviral therapy by modulating the body’s immune response through its mechanisms of action to fight viral infections such as HBV and RSV.

Contact:
Maeve Conneighton
Argot Partners
(212) 600-1902
[email protected]